Market Research Report
Anti-Infective Agents - Global Market Outlook (2017-2023)
|Published by||Stratistics Market Research Consulting||Product code||599889|
|Published||Content info||134 Pages
Delivery time: 2-3 business days
|Anti-Infective Agents - Global Market Outlook (2017-2023)|
|Published: December 1, 2017||Content info: 134 Pages||
According to Stratistics MRC,the Global Anti-Infective Agents Market is accounted for $86.7 billion in 2016 and expected to grow at a CAGR of 3.8% to reach $113.16 billion by 2023. Rising incidences of infectious diseases such as HIV, H1N1, and Ebola virus, awareness amongst the patients, commercialization of pipeline products, Govt collaborating with pharmaceutical companies for the development of new agents, development of new multi-drug resistance against micro-organisms are boosting the market growth. Treatment rates for communicable diseases in developing countries and treatment of Community Acquired Bacterial Pneumonia (CABP) are expected to impart the market growth. Growing resistance of infection to the drug therapies, high price of drugs, competition between generic manufacturers and perilous reimbursement policies will impede market growth.
Based on Product, most of the Antibacterial agents are in pipeline for the modifications of existing antibiotic classes. More innovative products are required against pathogens with no cross- or co-resistance to existing classes. Many of the products in the clinical pipeline are already funded by research grants from public and philanthropic institutions.For instance, Delafloxacin was approved by the US Food and Drug Administration on 21 June 2017.
North America commanded the anti-infective agents market and is followed by Europe. Asia Pacific is the fastest growing market due to improvements in healthcare infrastructure, demand for drugs and ongoing government initiatives for various control programs.
Some of the key players in Global Anti-Infective Agents market are Pfizer Ltd, Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd., AstraZeneca Plc, Boehringer Ingelheim, Bristol-Myers Squibb Co, Abbott Laboratories, Bayer Healthcare AG, Cipla Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Merck & Co., Inc, Novartis AG, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Panacea Biotech Ltd and Claris Life Sciences Ltd.
What our report offers:
Note: North America, Europe, Asia Pacific, South America, Middle East and Africa are represented in above manner.